. Author manuscript; available in PMC: 2015 Jun 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2014 Feb 16;20(6):787–793. doi: 10.1016/j.bbmt.2014.02.010

Table 2. Comparison of recipient and graft demographics in 125 patients with no or low HHV-6 viremia versus high level HHV-6 viremia.

Characteristics	No or Low Level Viremia (< 10,000 copies/mL, n = 74)	High Level Viremia (≥ 10,000 copies/mL, n = 51)	P value

Median age	42 years (range 1-69)	43 years (range 1-64)	0.89

Median weight	70 kg (range 8-104)	65 kg (range 10-125)	0.13

Diagnosis, N (%)
Acute leukemia, MDS, CML (n = 79)	41 (52%)	38 (48%)	0.05
Lymphoma inc. CLL (n = 46)	33 (72%)	13 (28%)

Conditioning, N (%)
TBI-based myeloablative (n = 78)	44 (56%)	34 (44%)	0.26
Chemo-based myeloablative (n = 16)	8 (50%)	8 (50%)
Non-myeloablative (n = 31)	22 (71%)	9 (29%)

Median unit-recipient HLA-match^*
A, -B antigen, -DRB1 allele	5/6 (range 4-6/6)	5/6 (range 4-6/6)	0.55
10 allele	6/10 (range 2-9/10)	6/10 (range 3-9/10)	0.13

Median dose
Infused TNC × 10⁷/kg^*	2.0 (range 1.2-11.3)	2.2 (range 1.4-10.7)	0.08
Infused CD34⁺ × 10⁵/kg^*	1.0 (range 0.1-4.8)	0.9 (range 0.2-3.7)	0.57

Unit dominant in engraftment.

N indicates number; kg, kilogram; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; chemo, chemotherapy; HLA, human leukocyte antigen; TNC, total nucleated cell dose.